Antbodies to human kerctinocyte growth factor (KGF) and related pharmaceuticals

US5654405A · kind A · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Jeffrey S. Rubin · Rockville, US
• Paul Finch · Bethesda, US
• Stuart A. Aaronson · Great Falls, US

Key dates

• Filing date: May 31, 1995
• Grant date: Aug 5, 1997
• Expiry date: May 31, 2015

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/158
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various functional forms from spontaneously secreting cells or from DNA segments introduced into cells. These forms variously enable biochemical and functional studies of this novel protein as well as production of antibodies. Means are described for determining the level of expression of genes for the KGF protein, for example, by measuring mRNA levels in cells or by measuring antigen secreted in extracellular or body fluids.